The US Food and Drug Administration (FDA) has granted orphan drug designation to CervoMed’s lead investigational therapy neflamapimod for the treatment of frontotemporal dementia, a rare ...

Chardan downgraded CervoMed (CRVO) to Neutral from Buy without a price target after the company announced topline data from the Phase 2b RewinD-LB of neflamapimod, its only clinical stage asset ...

"We are pleased to have received Orphan Drug Designation as it implicitly recognizes the scientific rationale and potential for neflamapimod to treat this debilitating condition. Patients diagnosed ...

CervoMed shares rose 15% after receiving the Food and Drug Administration's orphan drug designation for neflamapimod, its frontotemporal dementia treatment. Shares were trading around $9.19.

The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant designed to inhibit p38 mitogen-activated protein kinase alpha ...

H.C. Wainwright analyst Raghuram Selvaraju downgraded CervoMed (CRVO) to Neutral from Buy without a price target saying the “disappointing” neflamapimod clinical data “creates uncertainty.” ...

The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has ...

The p38MAP kinase alpha enzyme inhibitor neflamapimod missed its primary and secondary endpoints in a phase II study of dementia with Lewy bodies, CervoMed said. Neurodegeneration in the cortical ...

(MENAFN- GlobeNewsWire - Nasdaq) Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to ...